In a Phase I trial, ZW25 in combination with chemotherapy demonstrated antitumor activity in patients with unresectable locally advanced or metastatic HER2+ breast cancer pre-treated with trastuzumab, T-DM1, and pertuzumab (50). The gene discussed is ERBB2; the disease is breast cancer.